Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

08 Aug 2018

Mylan eyes 'all alternatives' as quarterly profit falls short

Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.

02 Aug 2018

Special Report: Biotech incubator taps investors through in-house brokerage

By Elizabeth Dilts, Benjamin Lesser, Carl O'Donnell and Michael Erman

02 Aug 2018

Icahn, with sizable stake in Cigna, to oppose Express Scripts acquisition: WSJ

Billionaire investor Carl Icahn has a sizable stake in health insurer Cigna and plans to vote against its planned $52 billion acquisition of pharmacy benefits manager Express Scripts , the Wall Street Journal reported https://www.wsj.com/articles/carl-icahn-has-sizable-stake-in-cigna-plans-to-vote-against-express-scripts-deal-1533150217 on Wednesday.

01 Aug 2018

Pfizer CEO expects Trump to eliminate drug rebates

Pfizer Inc Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases, suggesting that U.S. drug pricing reforms may focus on middlemen rather than drugmakers. | Video

27 Jul 2018

Amgen profit beats Street view, will not raise prices again in 2018

Amgen Inc on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

26 Jul 2018

Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

26 Jul 2018

Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.

26 Jul 2018

Gilead CEO Milligan, Chairman Martin to step down

Gilead Sciences Inc said on Wednesday that Chief Executive Officer John Milligan and Chairman John Martin will step down as soon as the end of the year, ending a nearly 30-year run at the U.S. biotech company for both men.

24 Jul 2018

Lilly plans Elanco IPO, posts quarterly profit above estimates

Eli Lilly and Co said on Tuesday it would take its Elanco animal health business public and posted a better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.

12 Jul 2018

Trump told Pfizer CEO price hikes hurt his drug plan: source

NEW YORK/WASHINGTON U.S. President Donald Trump called Pfizer Chief Executive Ian Read on Tuesday to say the company's July 1 price hikes had complicated the administration's drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.


  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 37,947.88 + 284.32 +0.75%
Nikkei 22,270.38 + 78.34 +0.35%
Hang Seng 27,213.41 + 113.35 +0.42%
EUR/INR 80.162 +0.01%
USD/INR 70.090 +0.00%
GBP/INR 89.386 +0.02%
Gold 1,181.20 +5.00 +0.43%
Oil 65.92 +0.46 +0.70%
Corn 364.50 -0.75 -0.21%